C. Diff News and Research

RSS

Progress toward preventing initial and recurrent episodes of C. diff infection

Surgeons are making progress toward preventing initial and recurrent episodes of clostridium difficile colitis (C. difficile or C. diff), a vicious bacterial infection that is estimated to affect about 336,000 people each year, typically patients on antibiotics.

6 Oct 2012

Xenex's pulsed xenon UV more effective than bleach in decontaminating C. diff surfaces

Healthcare associated infections (also referred to as HAIs or hospital acquired infections) are the fourth leading cause of death in the United States, costing more than $30 billion each year. Evidence continues to mount that hospital cleanliness plays a role in the spread of HAIs, which are caused by deadly pathogens such as C. diff, MRSA, VRE and Acinetobacter.

19 Sep 2012

Viewpoints: Romney in WSJ column offers lessons from Bain; Ryan's ideological vote against curbing the deficit

My presidency would make it easier for entrepreneurs and small businesses to get the investment dollars they need to grow, by reducing and simplifying taxes; replacing Obamacare with real health-care reform that contains costs and improves care; and by stemming the flood of new regulations that are tying small businesses in knots.

26 Aug 2012

Hospital records link C.diff to 2 times more deaths than federal estimates indicate

A USA TODAY investigation shows that C. diff is far more prevalent than federal reports suggest. The bacteria is linked in hospital records to more than 30,000 deaths a year in the United States -- about twice federal estimates and rivaling the 32,000 killed in traffic accidents. It strikes about a half-million Americans a year.

17 Aug 2012

First Edition: August 16, 2012

In this Kaiser Health News video, Insuring Your Health columnist Michelle Andrews answers a reader question about what you can do when insurance only covers a portion of an ambulance bill.

16 Aug 2012

Survey of home healthcare practices related to infection control

A healthy boy was infected with antibiotic-resistant bacterium that was traced to his mother's nurse's bag left in the family's car after his mother's home healthcare visit to a patient with the same infection. Although the boy's infection and the patient's infection were never DNA tested, the coincidence was remarkable.

26 Jun 2012

MountainView Hospital first in Nevada to use Xenex’s room disinfection device

In an ongoing effort to improve patient safety, MountainView Hospital today announced it is the first hospital in Nevada to use Xenex Healthcare Services' innovative germ-zapping room disinfection technology to keep patients even safer from infections.

21 Jun 2012

BioMed Protect’s Sanotracin RTU rapidly and effectively kills C. difficile within 3 minutes

In the United States Clostridium difficile or "C. difficile" is now recognized as one of the most dangerous and fastest growing Healthcare Acquired Infections (HAIs) in existence. Now surpassing even Staphylococcus aureus (MRSA), C. difficile infections tripled between 2000 and 2005.

6 Jun 2012

UV disinfection may reduce CDI in hospitals and LTCFs

In a recently published article, "Decontamination with Ultraviolet Radiation to Prevent Recurrent Clostridium difficile Infection in 2 Roommates in a Long-Term Care Facility" (Infection Control and Hospital Epidemiology, 05/2012), researchers shared the results of a trial that used Tru-D SmartUVC to prevent coincident recurrent CDI episodes in roommates in a Long-Term Care Facility (LTCF).

2 Jun 2012

C. difficile infection on the rise

A study presented by Mayo Clinic researchers during Digestive Disease Week 2012 provides clear evidence that the number of people contracting the hard-to-control and treat bacterial infection Clostridium difficile (C. difficile or C. diff) is increasing, and that the infection is commonly contracted outside of the hospital.

22 May 2012

Some patients appear to be more predisposed for recurrent infection from C. diff

University of Cincinnati (UC) researchers have found that some patients appear to be more predisposed for recurrent infection from the bacterium Clostridium difficile, or C. diff, and that it may advance to a more serious inflammatory condition in those individuals.

22 May 2012

T cell imbalance may put certain people at increased risk of C. difficile infection

University of Cincinnati (UC) researchers have found that an imbalance in the regulation of certain T cells-the cells in the body that fight off infection or attack the system in certain autoimmune diseases-may put certain people at a higher risk of having recurrent cases of Clostridium difficile, or C. Diff, infection.

22 May 2012

FDA clears Great Basin’s first C. diff molecular diagnostic test

Great Basin Corporation, a privately-held life sciences company developing sample-to-result molecular diagnostic solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for its first molecular diagnostic test for Clostridium difficile.

2 May 2012

Simple device for disinfecting stethoscopes

According to the Centers for Disease Control and Prevention (CDC) 1,900,000 people contract infections in hospitals, (Hospital Acquired Infections - HAIs) every year and well over 99,000 die as a result; more deaths than from AIDS, breast cancer and auto accidents combined.

12 Mar 2012

Acid reducing drugs could raise risk of C. diff diarrhea

U.S. health regulators, the Food and Drugs Administration (FDA), have announced that ulcer drugs such as AstraZeneca Plc's blockbuster Nexium could increase the risk of Clostridium difficile-associated diarrhea (CDAD).

9 Feb 2012

Great Basin seeks FDA 510(k) approval for C. difficile molecular diagnostic test

Great Basin Corporation, a privately held life sciences company developing sample-to-result molecular diagnostic solutions, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its first molecular diagnostic test for Clostridium difficile (C. diff).

14 Nov 2011

Powerful new antibiotic treatment for MRSA and C. difficile bugs

MGB Biopharma, a biopharmaceutical company which has licensed technology from the University of Strathclyde in Glasgow, Scotland, is developing a powerful new antibiotic treatment for resistant infections including the deadly MRSA and Clostridium difficile (C. diff.) bugs.

20 Sep 2011

Cone Health uses Xenex room disinfection systems to reduce HAI rates and costs

Cone Health today announced a dramatic reduction in healthcare-acquired infection (HAIs) rates after implementing an infection prevention program which includes Xenex room disinfection systems.

25 Aug 2011

Hospital acquired Clostridium difficile bug defense system identified

American researchers have discovered the process by which the cells in the gut fight off toxins produced by a hospital bug - Clostridium difficile. Writing in Nature Medicine, they showed how a chemical - GSNO - deactivated a toxin from Clostridium difficile which causes inflammation and diarrhea. They hope to use their findings to develop a treatment for C. difficile.

23 Aug 2011

Research uncovers natural defense mechanism that inactivates C. diff toxins

Groundbreaking research encompassing Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, has uncovered a natural defense mechanism that is capable of inactivating the toxin that spreads Clostridium difficile, or C. diff, an increasingly common bacterial infection in hospitals and long-term care settings.

22 Aug 2011